Actinium Pharmaceuticals Grants Equity Awards to New CFO, Business Development Chief

Bitget2026/10/16 21:00

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Actinium Pharmaceuticals granted CFO Matt David a non-qualified stock option covering 250,000 shares on October 14, 2026, exercisable at $0.97 per share.
David also received 250,000 restricted stock units vesting over three years, with up to 75,000 additional units tied to corporate milestones.
Senior Vice President, Business Development Sean Maenpaa received a non-qualified stock option covering 40,000 shares on October 12, 2026, exercisable at $1.06.
Maenpaa received 20,000 restricted stock units vesting annually over three years; another 50,000 vest at year three, subject to corporate milestones.
Both options have ten-year terms, vesting 28% after one year, then 2% monthly for 36 months; all awards require continued service.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Actinium Pharmaceuticals Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202610161700PR_NEWS_USPR_____NY74541) on October 16, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Actinium Pharmaceuticals Grants Equity Awards to New CFO, Business Development Chief

You may also like

Crypto prices